Astellas Pharma Inc. (OTCMKTS:ALPMY) Short Interest Update

Astellas Pharma Inc. (OTCMKTS:ALPMY) was the target of a large increase in short interest in the month of October. As of October 15th, there was short interest totalling 45,100 shares, an increase of 16.2% from the September 30th total of 38,800 shares. Based on an average daily trading volume, of 182,400 shares, the days-to-cover ratio is currently 0.2 days.

Astellas Pharma Stock Performance

Astellas Pharma stock opened at $12.30 on Thursday. Astellas Pharma has a 12-month low of $9.15 and a 12-month high of $13.14. The company has a market capitalization of $22.25 billion, a price-to-earnings ratio of 175.64 and a beta of 0.37. The company has a debt-to-equity ratio of 0.26, a current ratio of 0.90 and a quick ratio of 0.72. The firm’s fifty day moving average price is $11.97 and its 200 day moving average price is $10.81.

Astellas Pharma (OTCMKTS:ALPMY) last posted its quarterly earnings data on Thursday, August 1st. The company reported $0.24 earnings per share (EPS) for the quarter. Astellas Pharma had a return on equity of 7.79% and a net margin of 1.17%. The company had revenue of $3.03 billion for the quarter. On average, research analysts forecast that Astellas Pharma will post 0.54 EPS for the current fiscal year.

Astellas Pharma Company Profile

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.